APA (7th ed.) Citation

JN, G., N, A., BR, P., DD, C., AR, B., AJ, Y., & NS, R. (2026). Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T. Blood cancer journal, 16(1), . https://doi.org/10.1038/s41408-026-01510-1

Chicago Style (17th ed.) Citation

JN, Gustine, Attar N, Puliafito BR, Cirstea DD, Branagan AR, Yee AJ, and Raje NS. "Validation and Refinement of the New Consensus Genomic Staging (CGS) of High-risk Multiple Myeloma (HRMM) in Relapsed and Refractory Patients Treated with BCMA CAR-T." Blood Cancer Journal 16, no. 1 (2026). https://doi.org/10.1038/s41408-026-01510-1.

MLA (9th ed.) Citation

JN, Gustine, et al. "Validation and Refinement of the New Consensus Genomic Staging (CGS) of High-risk Multiple Myeloma (HRMM) in Relapsed and Refractory Patients Treated with BCMA CAR-T." Blood Cancer Journal, vol. 16, no. 1, 2026, https://doi.org/10.1038/s41408-026-01510-1.